News
$Aldeyra Therapeutics(ALDX.US$ Moomoo 24/7· 2 mins ago
Aldeyra Therapeutics' Phase 2 Trial Of ADX-629 For Atopic Dermatitis Shows Statistically Significant And Clinically Relevant Improvement In Investigator-assessed And Patient-reported Outcomes Across Different Physiological And Psychosocial Assessments![]()
Aldeyra Therapeutics' Phase 2 Trial Of ADX-629 For Atopic Dermatitis Shows Statistically Significant And Clinically Relevant Improvement In Investigator-assessed And Patient-reported Outcomes Across Different Physiological And Psychosocial Assessments
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
